Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today ...

AstraZeneca’s $4.5 billion investment in Albemarle County is set to create 600 jobs and strengthen Charlottesville’s biotech ...

Piramal Pharma anticipates growth revival in FY 2027 despite challenges, following a transitional FY 2026 marked by losses.

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

The pair will harness AI to discover and develop recombinases for precise, large-scale gene editing.

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory ...

Frontier Scientific Solutions ("Frontier"), a leading provider of cGMP-compliant, temperature-controlled logistics solutions, ...

Nandini Piramal, Chairperson of Piramal Pharma, said the company is seeing stronger RFP inflows and has added new products to ...

Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position ...

Dr. Reddy’s Laboratories (DRL) has secured Health Canada's first-ever generic Semaglutide approval, targeting the world's ...

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA ...

SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...